EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Polygenic Risk Score als Prädiktor für Knochenfraktur oder Osteoporose bei Prostatakrebspatienten unter Androgendeprivationstherapie

Ying-Qiang Liu, Li-Wen Chang, Hui-Wen Yang, Jian-Ri Li, Yi-Ming Chen iD, Sheng-Chun Hung, I-Chieh Chen iD

Cancer Medicine · 2025-11 · 14 (22)

DOI: 10.1002/cam4.71395 ↗

Auf einen Blick

Bei 903 Prostatakrebspatienten unter ADT waren bestimmte PRS mit einem höheren Risiko für Knochenereignisse verbunden. PGS002632 zeigte die stärkste Assoziation.

Fragestellung

Wie gut sagen polygenetische Risikoscores Knochenfraktur oder Osteoporose bei Prostatakrebspatienten unter ADT voraus?

Methode

Hospitalkohortenstudie; 24.778 männliche Teilnehmende, darunter 903 Prostatakrebspatienten; 9 PRS aus dem PGS Catalog; Cox-Regression nach PRS-Quartilen.

Ergebnisse

PGS002632, PGS002681 und PGS001955 hatten die höchsten AUCs. Für PGS002632 war das Risiko unter ADT in Q1 höher als in Q4 (HR 5,934; p = 0,0013). In Q1 war unter ADT das Risiko höher als ohne ADT (HR 3,698; p = 0,0093).

Schlussfolgerung der Autor:innen

Die Autoren sehen PRS als potenziellen Biomarker für das Risiko von Knochenfraktur und Osteoporose bei Prostatakrebspatienten unter ADT.

Kernaussagen

  • Bestimmte PRS waren mit Knochenereignissen unter ADT assoziiert.
  • PGS002632 zeigte die stärkste Vorhersageleistung.
  • Hospitalbasierte Kohorte bei Han-Chinesen.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.11.2025. Verfasst von Ying-Qiang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Osteoporosis, Fractures, Bone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taichung Veterans General Hospital.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The association between single nucleotide polymorphisms (SNPs) and fracture risk has been established in various studies. Androgen‐deprivation therapy (ADT) for prostate cancer, while extending survival, increases the risk of osteoporosis and bone fracture. This study aimed to assess the predictive value of polygenic risk scores (PRSs) on bone events among prostate cancer patients undergoing ADT.

Methods

We enrolled 24,778 male participants, including 903 prostate cancer patients treated at Taichung Veterans General Hospital. These patients were divided into ADT and non‐ADT groups. Nine PRSs related to bone mineral density from the PGS Catalog were tested and categorized into quartiles. Cox proportional hazards regression analysis was performed to evaluate the risk of bone fracture and osteoporosis between groups by PRS quartiles.

Results

Among the PRSs, PGS002632, PGS002681, and PGS001955 demonstrated the highest areas under the curve (AUCs) for predicting bone events. For PGS002632, the risk was significantly higher in the first quartile (Q1) compared to the fourth quartile (Q4) for patients receiving ADT (HR = 5.934, p = 0.0013), after adjusting for age and comorbidities. Furthermore, within the subgroup of prostate cancer patients in Q1 of PGS002632, the risk was higher for those receiving ADT compared to those not receiving ADT (HR = 3.698, p = 0.0093). Similar results were observed for PGS002681 and PGS001955.

Conclusion

This hospital‐based cohort study among Han Chinese highlights PRS as a potential biomarker for bone fracture and osteoporosis risk in prostate cancer patients initiating ADT. It provides a basis for personalized risk assessment and early intervention with bone protective strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsOsteoporosisFractures, BoneMultifactorial InheritanceHumansMaleAgedPolymorphism, Single NucleotideMiddle AgedRisk FactorsBone DensityRisk AssessmentAged, 80 and overGenetic Risk Score

Stichwörter der Autor:innen

androgen deprivation therapybone fractureincidenceosteoporosispolygenic risk scoreprostate cancer

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Physical Medicine and Rehabilitation, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.

ORCID-Profile: Yi-Ming Chen, I-Chieh Chen

Förderung

  • National Science and Technology Council
  • Taichung Veterans General Hospital

Zitieren

APA

Liu, Y. Q., Chang, L. W., Yang, H. W., Li, J. R., Chen, Y. M., Hung, S. C., & Chen, I. C. (2025). Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy. Cancer Medicine, 14(22). https://doi.org/10.1002/cam4.71395

Vancouver

Liu YQ, Chang LW, Yang HW, Li JR, Chen YM, Hung SC, et al. Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy. Cancer Medicine. 2025;14(22). doi:10.1002/cam4.71395

BibTeX
@article{Liu2025,
  author = {Liu, Ying-Qiang and Chang, Li-Wen and Yang, Hui-Wen and Li, Jian-Ri and Chen, Yi-Ming and Hung, Sheng-Chun and Chen, I-Chieh},
  title = {Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {22},
  doi = {10.1002/cam4.71395}
}
Kostenlos starten →